🇺🇸·2h agoIndustry
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Publisher
B
Bristol-Myers Squibb News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Bristol-Myers Squibb News
- Region
- USA
- Scope
- Industry
- Published
- July 13, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bristolmyers2016ir.q4web.com
Leave the platform to read the original full article on the publisher site.
Source: Bristol-Myers Squibb News
Scope: Industry
Related coverage
More related coverage
GSK News/6h ago
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Santen Pharmaceutical/13h ago
Santen and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%
Otsuka Holdings RSS/13h ago
Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of September 1, 2026
Natco Pharma/13h ago